A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose

Inclusion Criteria

• •1. Clinically definite MS with disease duration (from onset) of at least 6 months.
• •2. Subjects must have had at least 1 documented relapse within the last year prior to study entry.
• •3. Subjects must have at least 1 and not more than 15 gadolinium (Gd)-enhancing lesions on the screening MRI scan.
• •4. Subjects must be relapse-free and not have taken corticosteroids (IV, IM and/or PO) within the 30 days prior to the screening visit.
• •5. Subjects must not have taken corticosteroids (IV, IM and/or PO) between the screening and baseline visits.
• •6. Subjects may be male or female. Women of child- bearing potential must practice a medically acceptable method of birth control. Acceptable methods include oral contraceptive, contraceptive patch, or double-barrier method (condom or IUD with spermicide).
• •7. Subjects must be between the ages of 18 and 50 years inclusive.
• •8. Subjects must be ambulatory, with a Kurtzke EDSS score of between 0 and 5 inclusive.
• •9. Subjects must be willing and able to give written informed consent prior to entering the study.